10234-77-2 Usage
Uses
Used in Pharmaceutical Industry:
3-Pyrazolidinone, 5-methyl-, monohydrochloride is used as a pharmaceutical intermediate for the synthesis of various medications. Its water solubility as a monohydrochloride salt facilitates its incorporation into formulations, enhancing the bioavailability and effectiveness of the resulting drugs.
Used in Pain Management:
In the field of analgesics, 3-Pyrazolidinone, 5-methyl-, monohydrochloride is used as a key component in the development of pain-relieving medications. Its role in the synthesis process contributes to the creation of effective pain management solutions.
Used in Mental Health Treatments:
For antidepressant and antipsychotic drugs, 3-Pyrazolidinone, 5-methyl-, monohydrochloride is utilized as a critical intermediate in their production. Its involvement in the synthesis of these medications aids in the treatment of various mental health conditions, improving the quality of life for patients.
The specific applications and reasons for using 3-Pyrazolidinone, 5-methyl-, monohydrochloride may vary depending on the pharmaceutical formulation and the targeted therapeutic area, highlighting its versatility and importance in the development of diverse medicinal products.
Check Digit Verification of cas no
The CAS Registry Mumber 10234-77-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,2,3 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 10234-77:
(7*1)+(6*0)+(5*2)+(4*3)+(3*4)+(2*7)+(1*7)=62
62 % 10 = 2
So 10234-77-2 is a valid CAS Registry Number.
InChI:InChI=1/C4H8N2O/c1-3-2-4(7)6-5-3/h3,5H,2H2,1H3,(H,6,7)
10234-77-2Relevant academic research and scientific papers
Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes
-
Page/Page column 18, (2008/06/13)
The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 to R6 and R7a, R7b, R7c are defined according to claim 1. Furthermore the present invention relates to processes for preparing educts and intermediates in the above processes and to intermediates as such.
PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES
-
Page/Page column 41, (2008/06/13)
The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 to R6 and R7a, R7b, R7c are defined according to claim 1. Furthermore the present invention relates to processes for preparing educts and intermediates in the above processes and to intermediates as such.
CRYSTALLINE FORM OF 1′-(1-METHYLETHYL)- 4′-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5′-METHYL-1H-PYRAZOL-3′-O-β-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
-
Page/Page column 26-27, (2008/06/13)
The invention relates to a crystalline form of 1′-(1-methylethyl)- 4′-[(2-fluoro-4- methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
